NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.32 +0.17 (+2.38 %) (As of 05/22/2019 03:36 AM ET)Previous Close$7.15Today's Range$7.21 - $7.4852-Week Range$3.39 - $9.52Volume67,200 shsAverage Volume175,291 shsMarket Capitalization$198.34 millionP/E RatioN/ADividend YieldN/ABeta2.61 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Receive SNDX News and Ratings via Email Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX Previous Symbol CUSIPN/A CIK1395937 Webhttp://www.syndax.com/ Phone781-419-1400Debt Debt-to-Equity Ratio0.01 Current Ratio6.24 Quick Ratio6.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.52 million Price / Sales130.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.53 per share Price / Book2.89Profitability EPS (Most Recent Fiscal Year)($2.92) Net Income$-73,960,000.00 Net Margins-4,539.55% Return on Equity-107.48% Return on Assets-71.52%Miscellaneous Employees38 Outstanding Shares27,096,000Market Cap$198.34 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its quarterly earnings data on Monday, May, 6th. The company reported ($0.53) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.03. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,539.55% and a negative return on equity of 107.48%. View Syndax Pharmaceuticals' Earnings History. When is Syndax Pharmaceuticals' next earnings date? Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Syndax Pharmaceuticals. What price target have analysts set for SNDX? 7 analysts have issued 1-year price objectives for Syndax Pharmaceuticals' stock. Their predictions range from $5.00 to $26.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $15.6667 in the next twelve months. This suggests a possible upside of 114.0% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals. What is the consensus analysts' recommendation for Syndax Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals. Has Syndax Pharmaceuticals been receiving favorable news coverage? Media headlines about SNDX stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Syndax Pharmaceuticals' key competitors? Some companies that are related to Syndax Pharmaceuticals include CannTrust (CNTTF), Axsome Therapeutics (AXSM), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Principia Biopharma (PRNB), Cara Therapeutics (CARA), ArQule (ARQL), Y-mAbs Therapeutics (YMAB), ChemoCentryx (CCXI), Arvinas (ARVN), Vectura Group (VEGPF), Aptorum Group (APM), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI) and Emisphere Technologies (EMIS). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Verastem (VSTM), Cara Therapeutics (CARA), Idera Pharmaceuticals (IDRA), Progenics Pharmaceuticals (PGNX), Proteostasis Therapeutics (PTI), Micron Technology (MU) and Synergy Pharmaceuticals (SGYP). Who are Syndax Pharmaceuticals' key executives? Syndax Pharmaceuticals' management team includes the folowing people: Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)Mr. Michael A. Metzger, Pres & COO (Age 48)Mr. Richard P. Shea, CFO & Treasurer (Age 67)Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50) When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (12.24%), BlackRock Inc. (5.53%), Dimensional Fund Advisors LP (3.35%), Renaissance Technologies LLC (1.16%), Oxford Asset Management LLP (0.50%) and Morgan Stanley (0.25%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals. Which major investors are selling Syndax Pharmaceuticals stock? SNDX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Jacobs Levy Equity Management Inc. and Raymond James & Associates. View Insider Buying and Selling for Syndax Pharmaceuticals. Which major investors are buying Syndax Pharmaceuticals stock? SNDX stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Wellington Management Group LLP, Oxford Asset Management LLP, Parametric Portfolio Associates LLC, SG Americas Securities LLC, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $7.32. How big of a company is Syndax Pharmaceuticals? Syndax Pharmaceuticals has a market capitalization of $198.34 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe. What is Syndax Pharmaceuticals' official website? The official website for Syndax Pharmaceuticals is http://www.syndax.com/. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected] MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 235 (Vote Outperform)Underperform Votes: 247 (Vote Underperform)Total Votes: 482MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: 52-Week High/Low Prices For Stock Selection Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.